Sugi Predict

Sugi Predict / Compounds / SCHEMBL2975834

SCHEMBL2975834

SCHEMBL2975834

CC(C)CC(=O)Nc1ccc2sc(-c3ccnc(NCCN4C(=O)NC(=O)C4(C)C)n3)cc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SENP7 Q9BQF6 2/20 0.38
▸ IKBKB O14920 9/20 0.37
▸ CHUK O15111 7/20 0.37
▸ IKBKG Q9Y6K9 7/20 0.37
▸ RAB9A P51151 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ SYK P43405 4/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34
▸ MAPK1 P28482 2/20 0.33
▸ MAPK3 P27361 1/20 0.33
▸ TP53 P04637 2/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2983796 0.91 IKBKB (0.38) IKBKBCHUKIKBKGSYKMAPK1
SCHEMBL2983663 0.90 IKBKB (0.39) IKBKBCHUKIKBKGSYKMAPK1
SCHEMBL2976742 0.89 IKBKB (0.38) IKBKBCHUKIKBKGSYKMAPK1
SCHEMBL3177282 0.88 IKBKB (0.41) IKBKBCHUKIKBKGSYKMAPK1
SCHEMBL2988932 0.88 IKBKB (0.46) IKBKBCHUKIKBKGSYK
SCHEMBL2975941 0.88 IKBKB (0.38) IKBKBCHUKIKBKGSYKMAPK1
SCHEMBL2974915 0.87 IKBKB (0.35) IKBKBCHUKIKBKGSMN1; SMN2SYK
SCHEMBL2980831 0.87 IKBKB (0.37) IKBKBCHUKIKBKGSYKMAPK1
SCHEMBL2984268 0.86 PDGFRB (0.46) IKBKBCHUKIKBKGSYKMEN1
SCHEMBL2983547 0.86 IKBKB (0.41) IKBKBCHUKIKBKGSYKMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 — — EP disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 — — US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 — — US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 — — US disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 — — EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 — — US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 SENP7 3750/4885IKBKB 1952/4885CHUK 1311/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 SENP7 3750/4885IKBKB 1952/4885CHUK 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.